A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
Latest Information Update: 17 Feb 2025
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Melphalan (Primary) ; Melphalan (Primary) ; Cyclophosphamide; Prednisone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms EMN02/HOVON 95; HO95
- 21 Aug 2024 Planned End Date changed from 1 Apr 2024 to 1 Jan 2025.
- 22 Nov 2023 This study has been completed in Austria, according to European Clinical Trials Database record.
- 17 Aug 2023 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.